DOAC in Chinese Patients With Atrial Fibrillation

RecruitingOBSERVATIONAL
Enrollment

427

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

September 27, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial FibrillationStrokeStroke, AcuteBrain DiseasesMajor Adverse Cardiovascular EventArterial ThromboembolismVenous Thromboembolism
Interventions
DIAGNOSTIC_TEST

Blood Tests

Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.

Trial Locations (1)

Unknown

RECRUITING

Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER